Vitrolife AB (publ) (VITR.ST)
SEK 214.4
(1.13%)
SEK 214.4
(1.13%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.66 Billion SEK | -3.75% |
| 2022 | 3.81 Billion SEK | -6.77% |
| 2021 | 4.08 Billion SEK | 1319.05% |
| 2020 | 288.07 Million SEK | -15.54% |
| 2019 | 341.05 Million SEK | 69.47% |
| 2018 | 201.25 Million SEK | 3.86% |
| 2017 | 193.77 Million SEK | -15.79% |
| 2016 | 230.1 Million SEK | 7.39% |
| 2015 | 214.27 Million SEK | -20.61% |
| 2014 | 269.91 Million SEK | 63.38% |
| 2013 | 165.2 Million SEK | -9.83% |
| 2012 | 183.21 Million SEK | 49.11% |
| 2011 | 122.87 Million SEK | 19.23% |
| 2010 | 103.05 Million SEK | 118.12% |
| 2009 | 47.24 Million SEK | -6.02% |
| 2008 | 50.27 Million SEK | 9.11% |
| 2007 | 46.07 Million SEK | -8.57% |
| 2006 | 50.39 Million SEK | 44.32% |
| 2005 | 34.92 Million SEK | -0.13% |
| 2004 | 34.96 Million SEK | -13.8% |
| 2003 | 40.56 Million SEK | -47.4% |
| 2002 | 77.11 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.64 Billion SEK | -0.76% |
| 2024 Q3 | 3.74 Billion SEK | -0.27% |
| 2024 Q2 | 3.75 Billion SEK | 3.16% |
| 2023 FY | 3.66 Billion SEK | -3.75% |
| 2023 Q4 | 3.66 Billion SEK | -2.16% |
| 2023 Q3 | 3.74 Billion SEK | -5.54% |
| 2023 Q2 | 3.96 Billion SEK | 5.92% |
| 2023 Q1 | 3.74 Billion SEK | -1.68% |
| 2022 Q1 | 3.99 Billion SEK | -2.32% |
| 2022 Q4 | 3.81 Billion SEK | 0.18% |
| 2022 FY | 3.81 Billion SEK | -6.77% |
| 2022 Q3 | 3.8 Billion SEK | -2.88% |
| 2022 Q2 | 3.91 Billion SEK | -1.9% |
| 2021 Q2 | 362.78 Million SEK | 8.77% |
| 2021 FY | 4.08 Billion SEK | 1319.05% |
| 2021 Q1 | 333.53 Million SEK | 15.78% |
| 2021 Q4 | 4.08 Billion SEK | 1020.76% |
| 2021 Q3 | 364.74 Million SEK | 0.54% |
| 2020 Q1 | 320.95 Million SEK | -5.89% |
| 2020 Q4 | 288.07 Million SEK | -2.22% |
| 2020 FY | 288.07 Million SEK | -15.54% |
| 2020 Q2 | 315.63 Million SEK | -1.66% |
| 2020 Q3 | 294.61 Million SEK | -6.66% |
| 2019 Q2 | 349.32 Million SEK | 23.46% |
| 2019 Q1 | 282.94 Million SEK | 40.59% |
| 2019 FY | 341.05 Million SEK | 69.47% |
| 2019 Q4 | 341.05 Million SEK | -6.48% |
| 2019 Q3 | 364.7 Million SEK | 4.4% |
| 2018 Q1 | 218.73 Million SEK | 12.88% |
| 2018 Q2 | 221.26 Million SEK | 1.16% |
| 2018 Q3 | 208.35 Million SEK | -5.83% |
| 2018 Q4 | 201.25 Million SEK | -3.41% |
| 2018 FY | 201.25 Million SEK | 3.86% |
| 2017 FY | 193.77 Million SEK | -15.79% |
| 2017 Q4 | 193.77 Million SEK | 9.78% |
| 2017 Q3 | 176.5 Million SEK | -17.31% |
| 2017 Q2 | 213.46 Million SEK | 2.01% |
| 2017 Q1 | 209.26 Million SEK | -9.06% |
| 2016 Q1 | 222.55 Million SEK | 3.87% |
| 2016 Q4 | 230.1 Million SEK | -1.29% |
| 2016 Q3 | 233.12 Million SEK | 0.03% |
| 2016 Q2 | 233.05 Million SEK | 4.72% |
| 2016 FY | 230.1 Million SEK | 7.39% |
| 2015 Q1 | 218.61 Million SEK | -19.0% |
| 2015 Q4 | 214.27 Million SEK | 11.5% |
| 2015 Q3 | 192.17 Million SEK | -12.68% |
| 2015 Q2 | 220.07 Million SEK | 0.67% |
| 2015 FY | 214.27 Million SEK | -20.61% |
| 2014 Q3 | 170.09 Million SEK | 4.99% |
| 2014 Q4 | 269.91 Million SEK | 58.68% |
| 2014 Q2 | 162 Million SEK | 4.3% |
| 2014 Q1 | 155.33 Million SEK | -5.98% |
| 2014 FY | 269.91 Million SEK | 63.38% |
| 2013 Q4 | 165.2 Million SEK | 1.69% |
| 2013 Q2 | 186.86 Million SEK | 3.84% |
| 2013 Q1 | 179.94 Million SEK | -1.78% |
| 2013 Q3 | 162.46 Million SEK | -13.06% |
| 2013 FY | 165.2 Million SEK | -9.83% |
| 2012 Q1 | 123.82 Million SEK | 0.77% |
| 2012 Q4 | 183.21 Million SEK | -65.0% |
| 2012 FY | 183.21 Million SEK | 49.11% |
| 2012 Q2 | 144.49 Million SEK | 16.69% |
| 2012 Q3 | 523.51 Million SEK | 262.32% |
| 2011 Q3 | 122.76 Million SEK | 2.94% |
| 2011 Q1 | 110.93 Million SEK | 7.64% |
| 2011 Q2 | 119.26 Million SEK | 7.51% |
| 2011 FY | 122.87 Million SEK | 19.23% |
| 2011 Q4 | 122.87 Million SEK | 0.09% |
| 2010 FY | 103.05 Million SEK | 118.12% |
| 2010 Q4 | 103.05 Million SEK | 70.41% |
| 2010 Q3 | 60.47 Million SEK | 5.86% |
| 2010 Q2 | 57.12 Million SEK | 0.0% |
| 2009 Q4 | 47.24 Million SEK | 0.0% |
| 2009 FY | 47.24 Million SEK | -6.02% |
| 2008 FY | 50.27 Million SEK | 9.11% |
| 2007 FY | 46.07 Million SEK | -8.57% |
| 2006 FY | 50.39 Million SEK | 44.32% |
| 2005 FY | 34.92 Million SEK | -0.13% |
| 2004 FY | 34.96 Million SEK | -13.8% |
| 2003 FY | 40.56 Million SEK | -47.4% |
| 2002 FY | 77.11 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -33251.518% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | -37.163% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | -37.163% |
| Arcoma AB | 33.3 Million SEK | -10913.361% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | -1012.527% |
| BICO Group AB (publ) | 3.26 Billion SEK | -12.357% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | -1210.468% |
| CellaVision AB (publ) | 212.32 Million SEK | -1627.557% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -25736.444% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -53299.805% |
| C-Rad AB (publ) | 122.4 Million SEK | -2896.732% |
| Duearity AB (publ) | 17.53 Million SEK | -20824.13% |
| Dignitana AB (publ) | 37.56 Million SEK | -9663.889% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -18425.253% |
| Getinge AB (publ) | 24.69 Billion SEK | 85.147% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -17705.562% |
| Iconovo AB (publ) | 14.55 Million SEK | -25102.879% |
| Integrum AB (publ) | 22.07 Million SEK | -16517.691% |
| Luxbright AB (publ) | 7 Million SEK | -52299.102% |
| Mentice AB (publ) | 163.55 Million SEK | -2142.684% |
| OssDsign AB (publ) | 105.25 Million SEK | -3384.804% |
| Paxman AB (publ) | 44.5 Million SEK | -8141.03% |
| Promimic AB (publ) | 16.15 Million SEK | -22603.641% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -5800.047% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -17138.462% |
| ScandiDos AB (publ) | 37.18 Million SEK | -9763.927% |
| Sectra AB (publ) | 1.64 Billion SEK | -123.475% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -8224.633% |
| Senzime AB (publ) | 58.06 Million SEK | -6217.058% |
| SpectraCure AB (publ) | 14.97 Million SEK | -24394.157% |
| Stille AB | 172.64 Million SEK | -2024.652% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | -1363.886% |